Pharmaceutical products distributor, Shanghai Pharmaceuticals, is seeking to raise around $2.13 billion from its Hong Kong IPO, Reuters reports. The Chinese company will sell 664 million primary shares for $2.9-3.21 per share. Credit Suisse, Deutsche Bank and Goldman Sachs are the joint global coordinators and book-runners on the deal. CICC is the joint book-runner for the transaction.
Click here for the story from Reuters.
Click here for additional coverage from Pharma Times.